High-Dose Flu Vaccine Tied to Lower Alzheimer Risk
Key Clinical Summary
- High-dose influenza vaccination was associated with a greater reduction in Alzheimer disease (AD) risk compared with standard-dose vaccines in adults ≥65 years.
- In a cohort of nearly 200,000 older adults, high-dose vaccination reduced Alzheimer risk by ~55% versus ~40% with standard-dose vaccines.
- Protective effects appeared more pronounced in women, suggesting possible sex-based immunologic differences.
High-dose influenza vaccination may confer additional neuroprotective benefit beyond standard-dose formulations, according to results from a new, large retrospective cohort study published in Neurology. The findings highlight a potential preventive strategy for Alzheimer disease (AD) in older adults.
The study, lead by Paul Schulz, MD, director, Neurocognitive Disorders Center, UTHealth Houston Neurosciences, builds on previous research from 2022 which found that adults 65 years and older who received the flu vaccine had a reduced risk for Alzheimer disease.
Study Findings
Investigators analyzed data spanning 2014 to 2019 from a US health care claims database encompassing nearly 200,000 adults aged 65 years and older who received either high-dose or standard-dose inactivated influenza vaccines.
The study was designed to prevent immortal time bias by using sequential nested trials to emulate a target trial. In analysis, researchers used inverse probability weighting to adjust for measured confounding, emulate randomization, and reduce selection bias. Intervention effects were estimated as risk difference, number needed to treat (NNT), and risk ratio. Confidence intervals were created via bootstrapping. Secondary analyses were conducted to examine potential effect modifiers, including sex.
The high-dose influenza vaccination group included 120,775 individuals (185,183 person-trials; mean age 74.4 years, SD 5.5; 57.3% female) and the standard-dose vaccination group included 44,022 individuals (53,918 person-trials; mean age 73.0, SD 6.1; 56.4% female). The high-dose was associated with a nearly 55% reduction in Alzheimer risk compared with a 40% reduction for the standard-dose 2 years postvaccination (minimum NNT = 185.2 at 25 months).
The protective effect was also found to last longer among women (months 1-13, minimum NNT = 416.7) than men (months 17-24, significant only in intention-to-treat analysis, minimum NNT = 232.6) suggesting potential biological differences in immune response or neuroprotection.
Clinical Implications
These findings have important implications for preventive neurology and geriatric care. Alzheimer disease remains a leading cause of morbidity in older adults, with limited disease-modifying therapies available. Identifying modifiable risk factors—such as vaccination strategies—offers a potentially scalable intervention.
High-dose influenza vaccines are already recommended for adults aged 65 years and older. This study suggests that their benefits may extend beyond infection prevention to include reduced risk of neurodegenerative disease.
Clinicians may consider these findings when discussing vaccination options with older patients, particularly those at elevated risk for dementia. The observed sex differences also raise questions about personalized prevention strategies.
However, as an observational analysis, the study cannot establish causality. Residual confounding and selection bias may influence outcomes, and randomized trials would be needed to confirm a direct protective effect.
Nonetheless, the magnitude of risk reduction and large sample size support further investigation into immunization as a component of Alzheimer disease prevention.
Expert Commentary
“High-dose influenza vaccination is associated with reduced AD risk compared with standard-dose vaccination in adults ≥65 years, with a stronger effect among women,” said Dr Schulz and coauthors. “Significant study limitations included duration of follow-up (≤3 years) and lack of sociodemographic, lifestyle, biomarker, and mortality data.
Further research is needed to clarify whether the observed difference reflects protection against influenza infection or non-infection–related mechanisms.”
References
